Abstract
To compare the effectiveness of biologics after rituximab (RTX) treatment in RA. The effectiveness of TNF-α inhibitors (TNFi), abatacept (ABA) or tocilizumab (TCZ) was examined in patients previously treated with RTX using clinical data collected in the Collaborative Registries for the Evaluation of Rituximab in RA Collaborative registry. Patients had stopped RTX 6 months or less prior to the new biologic and had a baseline visit within 21 days of starting the new biologic. Two hundred and sixty-five patients were analysed after 6 months of treatment. Patients on TCZ (n = 86) had a greater decline of DAS28-ESR and clinical disease activity index than patients on TNFi (n = 89) or ABA (n = 90). This effect was also seen after adjusting for baseline prednisone use and the number of previous biologics. The mean DAS28-ESR scores in patients on TCZ were 1.0 (95% CI: 0.2, 1.7) and 1.8 (95% CI: 1.0, 2.5) points lower than in patients on TNFi or ABA, respectively. In patients on TCZ, the clinical disease activity index was 9.4 (95% CI: 1.7, 16.1) and 8.1 (95% CI: 0.9, 15.3) points lower than on TNFi and ABA, respectively. Patients on TCZ more frequently had good EULAR responses than patients on TNFi or ABA (66 vs 31 vs 14%, P < 0.001). ...Continue Reading
References
Oct 20, 1998·Arthritis and Rheumatism·A M van GestelP L van Riel
Jul 21, 2000·Arthritis and Rheumatism·M KosinskiJ E Ware
Sep 16, 2005·The New England Journal of Medicine·Mark C GenoveseMaxime Dougados
May 18, 2006·Rheumatology·K L HyrichUNKNOWN British Society for Rheumatology Biologics Register
Sep 2, 2006·Arthritis and Rheumatism·Stanley B CohenUNKNOWN REFLEX Trial Group
May 1, 2007·Arthritis and Rheumatism·Axel FinckhUNKNOWN Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis
Jul 16, 2008·Annals of the Rheumatic Diseases·P EmeryJ Kremer
Jan 22, 2009·Annals of the Rheumatic Diseases·M C GenoveseT M Shaw
May 7, 2009·Annals of the Rheumatic Diseases·A FinckhUNKNOWN Arthritis
Dec 8, 2009·Rheumatic Diseases Clinics of North America·Jaap Fransen, Piet L C M van Riel
Dec 8, 2009·Rheumatic Diseases Clinics of North America·Daniel Aletaha, Josef S Smolen
Jan 22, 2010·Rheumatology International·Richa MishraCharles H Pritchard
Aug 19, 2010·Rheumatology·Ulrich A WalkerUNKNOWN Swiss Clinical Quality Management Programme in Rheumatic Diseases
Oct 6, 2011·Annals of the Rheumatic Diseases·Katerina ChatzidionysiouCem Gabay
Nov 3, 2011·The Journal of Rheumatology·Vibeke StrandDennis Revicki
Mar 16, 2012·Annals of the Rheumatic Diseases·Axel FinckhUNKNOWN physicians of SCQM-RA
Mar 22, 2013·Lancet·Cem GabayUNKNOWN ADACTA Study Investigators
Jan 5, 2014·Annals of the Rheumatic Diseases·Sudipto DasMaya H Buch
Jan 21, 2014·Annals of the Rheumatic Diseases·P EmeryA Finckh
Citations
Oct 12, 2015·Rheumatology·Patrick Verschueren
Apr 14, 2016·Ocular Immunology and Inflammation·Denis WakefieldStephan Thurau
Jun 25, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mar Maldonado-MontoroMiguel Ÿngel Calleja-Hernández
Dec 14, 2016·The Pharmacogenomics Journal·M Maldonado-MontoroM Ángel Calleja-Hernández
Feb 1, 2017·Autoimmunity Reviews·Denis WakefieldUNKNOWN pre-treatment assessment Review panel
Nov 21, 2018·Journal of Clinical Pharmacology·Alberto Jiménez MoralesCarlos García Collado
Jan 27, 2019·BMJ : British Medical Journal·Jacques-Eric GottenbergUNKNOWN French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries
Oct 13, 2017·American Journal of Therapeutics·Tristan PascartRené-Marc Flipo
May 10, 2020·Annals of the Rheumatic Diseases·Sizheng Steven ZhaoKazuki Yoshida
Jan 10, 2021·RMD Open·Nadia M T RoodenrijsPaco M J Welsing
Dec 5, 2020·Joint, Bone, Spine : Revue Du Rhumatisme·Javier NarváezEstíbaliz Loza
Apr 22, 2021·Clinical Rheumatology·Marco SebastianiUNKNOWN Contributors
Aug 2, 2019·Joint, Bone, Spine : Revue Du Rhumatisme·Gaëlle VialAnne Tournadre
Aug 20, 2021·Annals of the Rheumatic Diseases·György NagyJacob M van Laar